 Cytomegalovirus infections allogeneic bone marrow transplantation Cytomegalovirus CMV infection recipients allogeneic bone marrow transplants CMV-seropositive patients CMV-seronegative patients Sources infection reactivation latent endogenous virus blood products CMV-seropositive blood donors use marrow CMV-seropositive donor CMV-seronegative recipient common severe clinical syndrome CMV infection allogeneic transplant recipients interstitial pneumonia patients Risk factors CMV pneumonia old age total-body irradiation severe graft-vs.-host disease rapid diagnosis CMV pneumonia immunochemical staining bronchoalveolar lavage fluid centrifugation cell cultures CMV monoclonal antibodies treatment CMV pneumonia problematic therapy combination intravenous immune globulin IVIG ganciclovir survival rates previous trials antiviral therapy CMV-seronegative patients CMV infection pneumonia use CMV-seronegative blood products IVIG IVIG additional benefits infectious complications graft-vs.-host disease patients CMV-seronegative blood products CMV-seropositive patients effective prophylaxis CMV reactivation pneumonia clinical trial prophylactic ganciclovir way